Houston, TX, United States of America

Helen Huls

USPTO Granted Patents = 2 

 

Average Co-Inventor Count = 8.0

ph-index = 1

Forward Citations = 93(Granted Patents)


Company Filing History:


Years Active: 2017-2023

Loading Chart...
Loading Chart...
2 patents (USPTO):Explore Patents

Title: The Innovative Journey of Helen Huls

Introduction: Helen Huls is a distinguished inventor based in Houston, Texas, known for her groundbreaking contributions in the field of immunotherapy. With a strong dedication to advancing medical technologies, she has been granted two patents that reflect her innovative spirit and commitment to improving patient care.

Latest Patents: One of Helen's latest patents involves the human application of engineered chimeric antigen receptor (CAR) T-cells. This invention focuses on methods and compositions for immunotherapy that utilize modified T cells comprising a chimeric antigen receptor (CAR). Notably, the CAR-expressing T-cells are produced using electroporation combined with a transposon-based integration system. This innovative approach allows for the creation of CAR-expressing cells that require minimal ex vivo expansion or can be directly administered to patients for the treatment of diseases such as cancer.

Career Highlights: Helen Huls is currently affiliated with the University of Texas System, where she engages in research and development aimed at transforming immunotherapy into a more accessible and effective treatment option for patients. Her work has had a significant impact on the scientific community and continues to push the boundaries of what is possible in medical sciences.

Collaborations: Throughout her career, Helen has collaborated with skilled colleagues such as Hiroki Torikai and Ling Zhang. These partnerships have not only enhanced her research efforts but have also contributed to the advancement of innovative therapies in the field of cancer treatment.

Conclusion: Helen Huls exemplifies the spirit of innovation and dedication to improving healthcare through her patent work in engineered CAR T-cells. Her contributions underscore the importance of collaboration and perseverance in the pursuit of groundbreaking solutions that can change lives. As she continues her work at the University of Texas System, Helen remains a key figure in the ongoing exploration of immunotherapy advancements.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…